The purpose of this study is to collect medical information to monitor the ongoing safety of the J\&J MedTech devices and to understand how well they work when routinely used to treat participants with acute ischemic stroke (a condition caused by a blocked blood vessel in the brain).
Participant is 18 years of age or older at the time of consent
Informed Consent has been provided by the participant or the participants' legally authorized representative (LAR)
Participants with angiographic confirmation of acute ischemic stroke
A clinical decision has been made to treat the participant with an eligible Johnson & Johnson MedTech neuro-thrombectomy device independently and prior to enrollment in the study
Known pregnancy, as evidenced by positive pregnancy test for women of childbearing potential or breast feeding
Current involvement in an investigational (drug, device, etcetera) clinical study that may confound study endpoints. Sponsor approval is required prior to enrollment
The study population will include participants with angiographic confirmation of acute ischemic stroke who are scheduled to undergo/have undergone mechanical thrombectomy using one or more of the study devices as specified in the protocol.
Cohort
Prospective
Not listed
Revascularization (Modified Thrombolysis in Cerebrovascular Infarction [mTICI])
Revascularization is defined as achieving a specific minimum mTICI score, such as 2b or greater. mTICI is a 6-point grading system for determining the response of thrombolytic therapy for ischaemic stroke with grades as follows: mTICI 0 = no perfusion; mTICI 1 = penetration but not perfusion; mTICI 2a = some perfusion with distal branch filling of less than (\<)50 percent (%) of territory visualized; mTICI 2b = substantial perfusion with distal branch filling of \>=50% of territory visualized; mTICI 2c = near-complete perfusion; mTICI 3 = complete perfusion.
Percentage of Participants With Modified Rankin Scale (mRS) Score of <=2 or no Worsening at 90 Days
Percentage of participants with mRS score of \<=2, or no worsening from baseline, at 90 days will be reported. The mRS is a commonly used 7-point disability scale with possible scores ranging from 0 (no symptoms) to 6 (Death).
90-Day All-Cause Mortality
All mortality regardless of causes through 90 days post procedure will be reported.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
